KRAS ¾ïÁ¦Á¦ ½ÃÀå - ½ÃÀå ±Ô¸ð, ´ë»ó ȯÀÚ, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2034³â)
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
»óǰÄÚµå : 1705099
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 7,950 £Ü 11,502,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 11,925 £Ü 17,254,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 15,900 £Ü 23,005,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 23,850 £Ü 34,508,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

º» º¸°í¼­´Â ¹Ì±¹, EU 4°³±¹(µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ), ¿µ±¹, ÀϺ»ÀÇ KRAS ¾ïÁ¦Á¦ ½ÃÀå µ¿Çâ°ú ÇÔ²² KRAS ¾ïÁ¦Á¦ÀÇ ¿ª»çÀû ¹× ¿¹Ãø ¿ªÇп¡ ´ëÇØ »ó¼¼È÷ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÇöÀç Ä¡·á¹ý, ½Å¾à, °³º° Ä¡·áÁ¦ ½ÃÀå Á¡À¯À², 2020³â¿¡¼­ 2034³â±îÁö ÁÖ¿ä 7°³±¹ KRAS ¾ïÁ¦Á¦ ½ÃÀå ±Ô¸ð ÇöȲ ¹× ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÇöÀç KRAS ¾ïÁ¦Á¦ÀÇ Ä¡·á¹ý/¾Ë°í¸®Áò°ú ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ Æ÷°ýÇÏ¿© ÃÖÀûÀÇ ±âȸ¸¦ ¹ß±¼ÇÏ°í ½ÃÀå ÀáÀç·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

KRAS´Â RAS ½´ÆÛ ÆÐ¹Ð¸® ¶Ç´Â RAS À¯»ç GTPase·Î ¾Ë·ÁÁø ÀúºÐÀÚ GTP °áÇÕ ´Ü¹éÁú ±×·ì¿¡ ¼ÓÇÕ´Ï´Ù. ¾Ï À¯ÀüÀÚÀÎ Áã À°Á¾ ¹ÙÀÌ·¯½º(RAS)´Â ½ÅÈ£Àü´Þ¹°Áú·Î ÀÛ¿ëÇÏ¿© Á¤»ó ¹× ¾Ç¼º ¼¼Æ÷¿¡¼­ ¼¼Æ÷ÀÇ Áõ½Ä, ºÐÈ­ ¹× »ýÁ¸À» Á¶ÀýÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, RAS-ºÐ¿­ÃËÁøÀÎÀÚ È°¼ºÈ­ ´Ü¹éÁú Ű³ª¾ÆÁ¦-ERK Ű³ª¾ÆÁ¦-¼¼Æ÷¿Ü ½ÅÈ£°ü·Ã Ű³ª¾ÆÁ¦(RAS-RAF-MEK-ERK-ERK) °æ·Î°¡ °¡Àå Àß ¾Ë·ÁÁø ½ÅÈ£Àü´Þ°æ·ÎÀÔ´Ï´Ù. (ERK) °æ·Î´Â °¡Àå Àß ¾Ë·ÁÁø ½ÅÈ£Àü´Þ °æ·Î Áß ÇϳªÀ̸ç, ±× ÀÌ»óÀº ÀϹÝÀûÀ¸·Î ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï ¹ß»ý¿¡ °ü¿©Çϸç, KRAS µ¹¿¬º¯ÀÌ´Â ¼¼Æ÷ ½ÅÈ£Àü´Þ °æ·ÎÀÇ ´Ü¹éÁúÀ» ¾ÏȣȭÇÏ´Â KRAS À¯ÀüÀÚÀÇ À¯ÀüÀû º¯ÀÌÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µ¹¿¬º¯ÀÌ´Â ´ëÀå¾Ï, Æó¾Ï, ÃéÀå¾Ï µî ´Ù¾çÇÑ Á¾·ùÀÇ ¾Ï¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ½À´Ï´Ù. ¾ÈŸ±õ°Ôµµ KRAS µ¹¿¬º¯ÀÌ´Â ¿ª»çÀûÀ¸·Î ƯÁ¤ Ä¡·áÁ¦·Î Ç¥ÀûÈ­Çϱ⠾î·Á¿ü½À´Ï´Ù. ±×·¯³ª ÃÖ±Ù ¿¬±¸ µ¿Çâ¿¡ µû¶ó KRAS µ¹¿¬º¯ÀÌ ¾ÏÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Àü·«ÀÌ °³¹ßµÇ°í ÀÖÁö¸¸, ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¸¸ ±¹ÇѵǾî ÀÖ½À´Ï´Ù.

ÀϹÝÀûÀ¸·Î KRAS µ¹¿¬º¯ÀÌ ¾ÏÀÇ Ä¡·á¿¡´Â ¼ö¼ú, ¹æ»ç¼± Ä¡·á, È­Çпä¹ý, Ç¥ÀûÄ¡·á, ¸é¿ª¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷ ÆóÀÇ ¹Ù±ùÂÊ °¡ÀåÀÚ¸®¿¡ °¡±î¿î ÀÛÀº Æó Á¾¾çÀÌ ÀÖ´Â °æ¿ì, ¼ö¼úÀ» °ßµðÁö ¸øÇÏ´Â ÀϺΠȯÀÚ¿¡°Ô´Â ¹æ»ç¼± ¼ÒÀÛ¿ä¹ý(RFA)ÀÌ °í·ÁµÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÆÇ ÁßÀÎ KRAS ¾ïÁ¦Á¦

LUMAKRAS/LUMYKRAS(¼ÒÆ®·¯½Ãºê) : Amgen

·ç¸¶Å¬·¡½º´Â RAS GTPase °è¿­ÀÇ ¾ïÁ¦Á¦·Î, KRAS G12C µ¹¿¬º¯À̰¡ ÀÖ´Â ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ºñ¼Ò¼¼Æ÷Æó¾Ï ¼ºÀΠȯÀÚ Áß ÃÖ¼Ò 1ȸ ÀÌ»óÀÇ Àü½Å Ä¡·á °æÇèÀÌ Àִ ȯÀÚÀÇ Ä¡·á¿¡ ÀûÀÀÁõÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ ¾àÀº 2021³â 5¿ù, ÃÖ¼Ò 1ȸ ÀÌ»óÀÇ Àü½ÅÄ¡·á °æÇèÀÌ ÀÖ´Â KRAS G12C À¯ÀüÀÚ º¯À̰¡ ÀÖ´Â ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î FDA°¡ ½ÂÀÎÇÑ °Ë»ç¸¦ ÅëÇØ Á¶±â Çã°¡¸¦ ȹµæÇß½À´Ï´Ù. ÀÌÈÄ À¯·´¿¬ÇÕ(EU)°ú ij³ª´Ù, ¿µ±¹ µî FDAÀÇ ÇÁ·ÎÁ§Æ® ¿À¸£ºñ½º(Project Orbis) ÀÌ´Ï¼ÅÆ¼ºê¿¡ Âü¿©ÇÑ ±¹°¡¸¦ Æ÷ÇÔÇÑ ´Ù¸¥ ±¹°¡¿¡¼­µµ ÆÇ¸Å ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. Ãß°¡ ÆÇ¸Å ½ÂÀÎ ½Åûµµ ÇöÀç ½É»ç ÁßÀÔ´Ï´Ù. À̹ø ½ÂÀÎÀº ¼ÒƲ¶ó½ÃºêÀÇ Áö¼ÓÀûÀÎ ¹ÝÀÀ°ú ¿ì¼öÇÑ ÇýÅÃ-À§Çè ÇÁ·ÎÆÄÀÏÀ» ÀÔÁõÇÏ´Â ¸Å¿ì Áß¿äÇÑ CodeBreaK 100 µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ÀÌ·ïÁ³½À´Ï´Ù. ·ç¸¶Å¬·¡½º´Â À¯·´¿¬ÇÕ, ¿µ±¹, ½ºÀ§½º¿¡¼­ ·ç¹ÌŬ·¡½º·Î ÆÇ¸ÅµÇ°í ÀÖÀ¸¸ç, 2023³â 8¿ù, ¾ÏÁ¨Àº ¹Ì±¹ FDA°¡ ·ç¸¶Å¬¶ó¿¡ BTD¸¦ ºÎ¿©Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

KRAZATI(Adaglacib) : Mirati Therapeutics

KRAZATI´Â FDA ½ÂÀÎ °Ë»ç¸¦ ÅëÇØ KRAS G12C À¯ÀüÀÚ º¯À̰¡ ÀÖ´Â ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î ÃÖ¼Ò ÇÑ ¹øÀÇ Ä¡·á °æÇèÀÌ ÀÖ´Â ¼ºÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ´Â °æ±¸¿ë Ç¥Àû Ä¡·áÁ¦·Î, 2022³â 12¿ù ¹Ì±¹¿¡¼­ ½ÃÆÇµÉ ¿¹Á¤ÀÔ´Ï´Ù. ½ÂÀεǾú½À´Ï´Ù. ½ÂÀÎÀº ´Ù±â°ü, ´ÜÀϱº, ¿ÀÇ ¶óº§ ÀÓ»ó½ÃÇè KRYSTAL-1(NCT03785249)¿¡ ±Ù°ÅÇÑ °ÍÀÔ´Ï´Ù. ÃÖ±Ù EC´Â 2024³â 1¿ù KRASG12C µ¹¿¬º¯ÀÌ ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾Ï ¹× ÃÖ¼Ò ÇÑ ¹øÀÇ Àü½Å Ä¡·á ÈÄ º´ÀÇ ÁøÇà¿¡ ´ëÇÑ Ä¡·áÁ¦·Î KRAZATI¿¡ ´ëÇÑ Á¶°ÇºÎ ÆÇ¸Å ½ÂÀÎÀ» ºÎ¿©Çß½À´Ï´Ù.

»õ·Î¿î KRAS ¾ïÁ¦Á¦

JDQ443 : ³ë¹ÙƼ½º

JDQ443Àº ±¸Á¶ ±â¹Ý ¾à¹° ¼³°è¸¦ ±â¹ÝÀ¸·Î µÎ °³ÀÇ À¯»çÇÏÁö ¾ÊÀº ÇÁ·ÎÅäŸÀÔÀ» ±¤¹üÀ§ÇÏ°Ô ÃÖÀûÈ­ÇÏ¿© ¾òÀº °øÀ¯ °áÇÕÇü KRAS G12C ¾ïÁ¦Á¦·Î, 5-methylpyrrazole ÄÚ¾î¿Í spiro-azetidine ¸µÄ¿¸¦ Æ÷ÇÔÇÏ´Â ¾ÈÁ¤ÇÑ ¾ÆÆ®·ÎÇǼҸÓÀÔ´Ï´Ù. ÀüÀÚ¼º ¾ÆÅ©¸±¾Æ¹Ìµå°¡ KRAS G12C¿¡ ÃÖÀûÀ¸·Î °áÇÕÇϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, JDQ443Àº ÀÌ º¯ÀÌÇü KRAS¸¦ ±¸Á¶ÀûÀ¸·Î ƯÀÌÀûÀ¸·Î ¾ïÁ¦ÇÏ¿© KRAS G12C¸¦ GDP °áÇÕÀÇ ºñȰ¼º »óÅ·ΠÆ÷ȹÇÏ´Â ÇÑÆí, ³»¼ºÀÇ °æ·Î·Î ÀνĵǴ H95¿ÍÀÇ Á÷Á¢Àû »óÈ£ÀÛ¿ëÀ» ÇÇÇÕ´Ï´Ù. ÇöÀç ÀÌ ¾àÀº ¹é±Ý ±â¹Ý È­Çпä¹ý°ú ¸é¿ª°ü¹®¾ïÁ¦Á¦ Ä¡·á¸¦ ¼øÂ÷ÀûÀ¸·Î ¶Ç´Â º´¿ë¿ä¹ýÀ¸·Î ¹ÞÀº ÀûÀÌ ÀÖ´Â KRAS G12C º¯À̰¡ ÀÖ´Â ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î JDQ443À» ´Üµ¶¿ä¹ýÀ¸·Î µµ¼¼Å¹¼¿°ú ºñ±³ÇÏ´Â ÀÓ»ó 3»ó ½ÃÇè(NCT05132075)À» ÁøÇà ÁßÀÔ´Ï´Ù. NCT05132075/KontRASt-02)¸¦ ÁøÇà ÁßÀÔ´Ï´Ù. ȸ»ç´Â 2024³â ÀÓ»ó 3»ó ´Üµ¶¿ä¹ý(2/3L) ½ÃÇèÀÇ µ¥ÀÌÅÍ µµÃâ ¹× NDA Á¦ÃâÀ» ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

µð¹Ù¶ó½Ãºê : Roche/Genentech

Divarasib(GDC-6036/RO7435846)Àº °æ±¸¿ë °íȰ¼º, ¼±ÅÃÀû KRAS G12C ¾ïÁ¦Á¦ÀÔ´Ï´Ù. ÀÌ ¾àÀº KRAS G12C ¿ÂÄڴܹéÁúÀ» ºñ°¡¿ªÀûÀ¸·Î ºÒȰ¼º »óÅ·Π°íÁ¤½ÃÄÑ Á¾¾ç¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ëÀ» ÇÕ´Ï´Ù. ºñ¼Ò¼¼Æ÷Æó¾Ï, ´ëÀå¾Ï, ±âŸ ¾ÏÁ¾À» Æ÷ÇÔÇÑ °íÇü¾Ï¿¡¼­ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÀüÀÓ»ó ¸ðµ¨¿¡¼­ KRAS G12C ´Ü¹éÁú¿¡ ´ëÇÑ °­·ÂÇÏ°í ¼±ÅÃÀûÀÎ ¾ïÁ¦ È¿°ú°¡ È®ÀεǾúÀ¸¸ç, GDC-6036Àº KRASG12C ´Ü¹éÁúÀÇ ½ºÀ§Ä¡ II Æ÷ÄÏ¿¡ ¼±ÅÃÀûÀ¸·Î °áÇÕÇÏ¿© 12¹øÂ° ½Ã½ºÅ×ÀÎ Àܱâ¿Í ƯÀÌÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ ºñȰ¼º GDP °áÇÕ »óÅ·Πºñ°¡¿ªÀûÀ¸·Î °íÁ¤Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ºñȰ¼º GDP °áÇÕ »óÅ·Πºñ°¡¿ªÀûÀ¸·Î Àá±âµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ȸ»ç Ãø¿¡ µû¸£¸é, 2L ºñ¼Ò¼¼Æ÷Æó¾ÏÀ» ´ë»óÀ¸·Î ÇÑ È®ÀÎÀû ÇǺ¸Å» 3»ó ½ÃÇèÀº 2022³â 4ºÐ±â¿¡ ½ÃÀ۵ƽÀ´Ï´Ù.

KRAS´Â PDAC, NSCLC, CRC¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¾Ï¿¡¼­ º¯À̵DZ⠽¬¿î ¾Ï À¯ÀüÀÚ·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¹¿¬º¯ÀÌ´Â ºÒ·®ÇÑ ¿¹ÈÄ ¹× ³ôÀº Ä¡»çÀ²°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µå¶óÀ̹ö À¯ÀüÀÚÀÇ ¹ß°ß°ú ƯÀÌÀû ¾ïÁ¦Á¦ÀÇ °³¹ß·Î ¾Ï Ä¡·áÀÇ Á¢±Ù¹ýÀÌ Å©°Ô º¯È­Çϰí ÀÓ»óÀû °á°úµµ °³¼±µÇ¾ú½À´Ï´Ù. Ç¥Àû Ä¡·á´Â ¹«ÁøÇà »ýÁ¸±â°£À» ¿¬ÀåÇϰí Ç¥ÁØ È­Çпä¹ýº¸´Ù µ¶¼ºÀÌ ³·Àº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ±×·¯³ª ¼ö½Ê ³â¿¡ °ÉÄ£ ¿¬±¸¿¡µµ ºÒ±¸Çϰí, KRAS(G12C)·Î ¾Ë·ÁÁø KRASÀÇ Æ¯Á¤ º¯ÀÌÇüÀ» Ç¥ÀûÀ¸·Î ½ÂÀÎµÈ ¼ÒƲ¶ó½Ãºê¿Í ¾Æ´Ù±×¶ó½Ãºê¿Í °°Àº ÃÖ±ÙÀÇ ¹ßÀüÀ» Á¦¿ÜÇϰí´Â KRAS º¯À̸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â È¿°úÀûÀÎ Àü·«Àº Á¦ÇÑÀûÀÔ´Ï´Ù. KRASÀÇ º»ÁúÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ ¾î·Á¿î °úÁ¦¿´½À´Ï´Ù. ±× °á°ú, ¿¬±¸ÀÚµéÀº ´Ù¿î½ºÆ®¸² ½ÅÈ£Àü´Þ ºÐÀÚ¸¦ Ç¥ÀûÀ¸·Î »ï°Å³ª, ÅڷθӶóÁ¦ ¾ïÁ¦Á¦³ª RNA °£¼·°ú °°Àº ÈÄ»ýÀ¯ÀüÇÐÀû ¹æ¹ýÀ» äÅÃÇϰųª, »çÀÌŬ¸° ÀÇÁ¸¼º Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦¸¦ Æ÷ÇÔÇÑ ÇÕ¼º Ä¡»ç Àü·«À» ÀÌ¿ëÇÏ´Â µî ´ëüÀûÀÎ Á¢±Ù¹ýÀ» ¸ð»öÇØ ¿Ô½À´Ï´Ù.

2021³â 5¿ù±îÁö µ¹¿¬º¯ÀÌ KRAS ´Ü¹éÁúÀÇ ¾Ï ÃËÁø ÀÛ¿ë¿¡ ´ëÇ×ÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Ä¡·á¹ýÀº ¾øÀ¸¸ç, FDA´Â ÀÌ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ·ç¸¶Å¬·¡½º(¼ÒƲ¶ó½Ãºê)¶ó´Â ¾à¹°À» Á¶±â¿¡ ½ÂÀÎÇß½À´Ï´Ù. ·ç¸¶Å¬·¡½º´Â ±¹¼Ò ÀüÀÌ(±¹¼Ò ÁøÇ༺) ¶Ç´Â ¿ø°Ý ÀüÀÌ(ÀüÀ̼º) ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇØ °í¾ÈµÈ ¾à¹°ÀÔ´Ï´Ù. ÀÌ È¯ÀÚµéÀº È­Çпä¹ý µî ´Ù¸¥ Àü½Å ¾Ï Ä¡·á¸¦ ÇÑ ¹ø ÀÌ»ó ¹ÞÀº ÀûÀÌ ÀÖ°í, Á¾¾ç¿¡ G12C·Î ¾Ë·ÁÁø KRAS µ¹¿¬º¯À̰¡ ÀÖ¾î¾ß ÇÕ´Ï´Ù.

2022³â 12¿ù, ¹Ì±¹ FDA´Â RAS GTPase °è¿­ ¾ïÁ¦Á¦ÀÎ KRAZATI(¾Æ´Ù±×¶ó½Ãºê)¸¦ KRAS G12C º¯À̰¡ ÀÖ´Â ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ºñ¼Ò¼¼Æ÷Æó¾Ï ¼ºÀΠȯÀÚ Ä¡·áÁ¦·Î Á¶±â ½ÂÀÎÇß½À´Ï´Ù. À̹ø ½ÂÀÎÀº 112¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ KRYSTAL-1 ÀÓ»ó½ÃÇèÀÇ °á°ú¿¡ µû¶ó °áÁ¤µÆ½À´Ï´Ù. ÀÌ È¯ÀÚµéÀº ÀÌÀü¿¡ ¹é±Ý ±â¹Ý È­Çпä¹ý ¹× ¸é¿ª°ü¹®¾ïÁ¦Á¦ Ä¡·á¸¦ ¹Þ¾ÒÀ¸¸ç, º´ÀÌ ÁøÇàµÈ »óÅ¿´½À´Ï´Ù.

Amgen°ú Mirati Therapeutics´Â ¾Ï Ä¡·á¸¦ À§ÇÑ KRAS ¾ïÁ¦Á¦ °³¹ß °æÀïÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ±×·¯³ª µÎ ȸ»çÀÇ ÇöÀç Èĺ¸¹°ÁúÀº G12C µ¹¿¬º¯ÀÌ Á¾¾ç¸¸À» Ç¥ÀûÀ¸·Î Çϰí ÀÖ¾î ´Ù¸¥ KRAS µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ´ëÀÀ¿¡´Â Å« °ÝÂ÷°¡ ÀÖ½À´Ï´Ù. ÇöÀç ´Ù¸¥ º¯ÀÌÇü¿¡ ´ëÇÑ ½ÂÀÎµÈ Ä¡·áÁ¦°¡ ¾ø±â ¶§¹®¿¡ ÀÌ ºÐ¾ß¿¡´Â Å« ¹ÌÃæÁ· ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÀνÄÇÑ ¸¹Àº ÁÖ¿ä ¿¬±¸ÀÚµéÀÌ KRAS º¯ÀÌü¸¦ Àû±ØÀûÀ¸·Î ¿¬±¸Çϰí ÀÖÀ¸¸ç, ºñ¼Ò¼¼Æ÷Æó¾Ï ÀÌ¿ÜÀÇ ´Ù¸¥ ¾ÏÀ¸·Î ¿¬±¸¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÊÁ¡ ÀüȯÀº º¸´Ù ±¤¹üÀ§ÇÑ KRAS µ¹¿¬º¯ÀÌ¿¡ ´ëÀÀÇÏ°í ¿©·¯ ¾ÏÁ¾À» Ç¥ÀûÀ¸·Î ÇÏ´Â È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Cardiff Oncology(onvansertib), Gritstone bio(SLATE KRAS), Hookipa PharmaÞä(HB-700)¸¦ ºñ·ÔÇÑ ¸¹Àº ±â¾÷µéÀÌ ¹ü KRAS¿¡ ´ëÇÑ Èĺ¸¹°Áú °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è KRAS ¾ïÁ¦Á¦ ½ÃÀåÀ» Á¶»çÇϰí 2020-2034³â KRAS ¾ïÁ¦Á¦ ½ÃÀå¿¡¼­ Ãâ½ÃµÉ °ÍÀ¸·Î ¿¹»óµÇ´Â ÀáÀçÀû KRAS ¾ïÁ¦Á¦ÀÇ Èí¼öÀ²¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ý ¹× ¾à¹° µµÀÔ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ºÐ¼®Àº º» º¸°í¼­¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÀÓ»ó 3»ó, ÀÓ»ó 2»ó, ÀÓ»ó 1»ó ´Ü°è¿¡ ÀÖ´Â ´Ù¾çÇÑ Ä¡·áÁ¦ Èĺ¸¹°Áú¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Ç¥Àû Ä¡·áÁ¦ °³¹ß¿¡ Âü¿©ÇÏ´Â ÁÖ¿ä ±â¾÷µé¿¡ ´ëÇÑ ºÐ¼®°ú ÇÔ²² KRAS ¾ïÁ¦Á¦ ½Å¾à °³¹ß °ü·Ã °øµ¿¿¬±¸, ÀμöÇÕº´, ¶óÀ̼±½Ì, ƯÇã¿¡ ´ëÇÑ ¼¼ºÎÀûÀÎ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Áß¿äÇÑ ÀλçÀÌÆ®

Á¦2Àå º¸°í¼­ ¼Ò°³

Á¦3Àå KRAS ¾ïÁ¦Á¦ ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä »ç°Ç

Á¦5Àå KRAS ¾ïÁ¦Á¦ ½ÃÀå °³¿ä

Á¦6Àå ¹è°æ°ú °³¿ä

Á¦7Àå ´ë»ó ȯÀÚ

Á¦8Àå Ãâ½ÃµÈ KRAS ¾ïÁ¦Á¦

Á¦9Àå KRAS ¾ïÁ¦Á¦ ½ÅÈï¾à

Á¦10Àå KRAS ¾ïÁ¦Á¦ ½ÃÀå : ÁÖ¿ä 7°³±¹ ºÐ¼®

Á¦11Àå KRAS ¾ïÁ¦Á¦ ¹ÌÃæÁ· ¼ö¿ä

Á¦12Àå KRAS ¾ïÁ¦Á¦ SWOT ºÐ¼®

Á¦13Àå KRAS ¾ïÁ¦Á¦ KOLÀÇ °ßÇØ

Á¦14Àå KRAS ¾ïÁ¦Á¦ ½ÃÀå Á¢±Ù°ú »óȯ

Á¦15Àå ºÎ·Ï

Á¦16Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦17Àå ¸éÃ¥»çÇ×

Á¦18Àå DelveInsight ¼Ò°³

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Key Highlights:

DelveInsight's "KRAS inhibitors Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the KRAS inhibitors, historical and forecasted epidemiology as well as the KRAS inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

KRAS inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM KRAS inhibitors market size from 2020 to 2034. The report also covers current KRAS inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

KRAS Inhibitors Treatment Market

KRAS inhibitors Overview

KRAS belongs to a group of small GTP-binding proteins known as the RAS superfamily or RAS-like GTPases. Rat sarcoma virus (RAS), an oncogene, functions as a signal transducer, important for regulating cell proliferation, differentiation, and survival in normal and malignant cells. The RAS-mitogen-activated protein kinase-ERK kinase-extracellular signal-related kinase (RAS-RAF-MEK-ERK) pathway is one of the best-characterized signal transduction pathways, and its aberrancies are commonly implicated in the development of multiple different cancer types. KRAS mutations are genetic alterations in the KRAS gene, which encodes a protein in cell signaling pathways. These mutations are commonly found in various types of cancer, including colorectal, lung, and pancreatic cancer. Unfortunately, KRAS mutations have historically been challenging to target with specific treatments. However, recent advancements in research have led to the development of some promising strategies to treat KRAS-mutated cancers, but these treatments are limited to NSCLC only.

Generally, treatment for KRAS-mutated cancers includes surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapy, and others. Radiofrequency ablation (RFA) might be considered for some people with small lung tumors near the outer edge of the lungs, especially if they cannot tolerate surgery.

KRAS Epidemiology

As the KRAS Inhibitor market is derived using a patient-based model, the KRAS inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, CRC, and Pancreatic Cancer, total KRAS incident cases in NSCLC, CRC, and Pancreatic Cancer, total KRAS variant cases in NSCLC, CRC, and Pancreatic Cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

KRAS Inhibitors Drug Chapters

The drug chapter segment of the KRAS inhibitors reports encloses a detailed analysis of KRAS inhibitors marketed drugs such as LUMAKRAS/LUMYKRAS and KRAZATI, and late-stage (Phase III and Phase II) pipeline drugs including JDQ443, Avutometinib, and others . It also helps understand the KRAS inhibitors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed KRAS Inhibitor Drugs

LUMAKRAS/LUMYKRAS (sotorasib): Amgen

LUMAKRAS is an inhibitor of the RAS GTPase family indicated for treating adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. The drug received accelerated approval from the FDA in May 2021 for treating patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization was subsequently granted in the European Union and additional countries, including some under FDA's Project Orbis initiative, such as Canada and the UK. Additional marketing applications are also under review. Approval was based on pivotal CodeBreaK 100 data demonstrating durable responses and a favorable benefit-risk profile with sotorasib. LUMAKRAS is marketed as LUMYKRAS in the European Union, the United Kingdom, and Switzerland. In August 2023, Amgen announced that the US FDA granted BTD to LUMAKRAS.

KRAZATI (adagrasib): Mirati Therapeutics

KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. KRAZATI received approval from the FDA and launched commercially in the US in December 2022. Approval was based on KRYSTAL-1, a multicenter, single-arm, open-label clinical trial (NCT03785249). Recently, in January 2024, the EC granted conditional marketing authorization for KRAZATI for treating KRASG12C -mutated advanced NSCLC and disease progression after at least one prior systemic therapy.

Emerging KRAS Inhibitor Drugs

JDQ443: Novartis

JDQ443 is an investigational covalent KRAS G12C inhibitor derived from a structure-based drug design followed by extensive optimization of two dissimilar prototypes. It is a stable atropisomer containing a unique 5-methyl pyrazole core and a spiro-azetidine linker designed to position the electrophilic acrylamide for optimal engagement with KRAS G12C. JDQ443 inhibits this mutated form of KRAS structurally distinctly, trapping KRAS G12C in a GDP-bound, inactive state while avoiding direct interaction with H95, a recognized route for resistance. Currently, this drug is in a Phase III trial (NCT05132075/KontRASt-02) designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced NSCLC harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. The company has anticipated the data readout of the Phase III monotherapy (2/3L) trial and NDA submission by 2024.

Divarasib: Roche/Genentech

Divarasib (GDC-6036/RO7435846) is an investigational, oral, highly potent, and selective KRAS G12C inhibitor. It works by irreversibly locking the KRAS G12C oncoprotein in its inactive state, preventing the tumor cells from growing. It is being investigated in solid tumors, including non-small cell lung cancer, colorectal cancer, and other cancer types. Preclinical models showed potent and selective inhibition of the KRAS G12C protein. GDC-6036 is designed to selectively bind to the switch II pocket of KRASG12C protein through a specific interaction with the cysteine residue at position 12 and irreversibly lock it in the inactive GDP-bound state. As per the company, a confirmatory pivotal Phase III trial in 2L+ NSCLC was initiated in Q4 2022.

KRAS Inhibitors Market Outlook

KRAS is a well-known oncogene highly prone to mutations in various cancers, including PDAC, NSCLC, and CRC. These mutations are associated with poor prognosis and high fatality rates. The discovery of driver genes and the development of specific inhibitors have significantly transformed cancer treatment approaches and improved clinical outcomes. Targeted therapies have been shown to prolong progression-free survival and exhibit lower toxicity than standard chemotherapy. However, despite several decades of research, there have been limited effective strategies for targeting KRAS mutations, except for recent advancements like sotorasib and adagrasib, which have been approved to target a specific mutated form of KRAS known as KRAS (G12C). Targeting KRAS directly has been a formidable challenge due to its intrinsic characteristics. As a result, researchers have explored alternative approaches, such as targeting downstream signaling molecules, employing epigenetic methods like telomerase inhibitors and RNA interference, and utilizing synthetic lethality strategies involving cyclin-dependent kinase inhibitors.

Until May 2021, no effective treatments were available to counteract the cancer-promoting actions of mutant KRAS proteins. The FDA granted accelerated approval to a drug called LUMAKRAS (sotorasib) to address this issue. LUMAKRAS is designed to treat patients with non-small cell lung cancer (NSCLC) that has either spread locally (locally advanced) or to distant parts of the body (metastatic). These patients must have previously undergone at least one other systemic cancer treatment, such as chemotherapy, and possess a specific KRAS mutation known as G12C in their tumors.

In December 2022, the US FDA granted accelerated approval to KRAZATI (adagrasib), a RAS GTPase family inhibitor, for treating adult patients with locally advanced or metastatic NSCLC carrying the KRAS G12C mutation. This approval was contingent on the results of the KRYSTAL-1 clinical trial, which involved 112 patients. These patients had previously undergone platinum-based chemotherapy and treatment with an immune checkpoint inhibitor, and their disease had progressed.

Amgen and Mirati Therapeutics are at the forefront of the race to develop KRAS inhibitors for cancer treatment. However, their current candidates are focused solely on targeting G12C-mutant tumors, leaving a significant gap in addressing other KRAS variants. This represents a major unmet need in the field, as no approved treatments are currently available for other variants. Recognizing this challenge, numerous key players actively explore alternative KRAS variants and expand their research to include other cancers beyond NSCLC. This shift in focus holds promising potential for developing effective therapies that can address a wider range of KRAS mutations and target multiple cancer types. Many companies are focusing on developing their candidates in pan-KRAS, like Cardiff Oncology (onvansertib), Gritstone bio (SLATE KRAS), Hookipa Pharma (HB-700), and others.

KRAS inhibitors Drugs Uptake

This section focuses on the uptake rate of potential KRAS Inhibitor drugs expected to be launched in the KRAS Inhibitor market during 2020-2034. Further detailed analysis of emerging therapies and drug uptake is in the report.

KRAS Inhibitors Pipeline Development Activities

The KRAS Inhibitor market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The KRAS Inhibitor market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for KRAS inhibitors emerging therapies.

KRAS Inhibitor KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on KRAS inhibitors evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Texas from UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or KRAS inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

KRAS Inhibitor Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited impact on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Mirati Therapeutics is committed to helping patients and their loved ones gain access to prescribed Mirati medications. When a patient enrolls in the Mirati & Me patient support program, the patient receives the resources and information to help them access their medication, manage costs, and navigate care, including coverage and access support, financial support, educational support, and emotional support.

Amgen's Assist 360 program helps patients reimburse their therapy costs low on their pocket. If the patient has government insurance (like Medicare), Amgen Assist 360 can refer them to independent, nonprofit patient assistance programs that may be able to help them afford their LUMAKRAS copay costs.

Scope of the KRAS Inhibitor Market Report

KRAS inhibitors market report insights

KRAS inhibitors Market Report key strengths

KRAS inhibitors Market Report assessment

Key Questions:

KRAS Inhibitor Market insights

KRAS Inhibitor Epidemiology insights

Current treatment scenario, marketed drugs, and emerging therapies

Reasons to buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of KRAS Inhibitors

4. Key Events

5. KRAS Inhibitors Market Overview At A Glance

6. Background And Overview

7. Target Population

8. KRAS Inhibitors Marketed Drugs

9. KRAS Inhibitors Emerging Drugs

10. KRAS Inhibitors Market: The 7MM Analysis

11. KRAS Inhibitor Unmet Needs

12. KRAS Inhibitor SWOT Analysis

13. KRAS Inhibitor KOL Views

14. KRAS Inhibitor Market Access and Reimbursement

15. Appendix

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â